knowledge -WSS

knowledge

author：explore 2025-09-29 01:09:14 - browse：9477

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Why workplace violence is so common in health care

WSS

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

First U.S. drug developed to treat liver disease MASH is approved

Trump lawyer welcomes Pence testifying in Jan. 6 trial, won't say if Trump will too

How many hemophilia patients actually want gene therapy?

Readout Newsletter: CAR

Amid AI frenzy, a top HHS official's quest to create safeguards

knowledge

knowledge

entertainment

Apple is now the first public company to be valued at $3 trillion

South Korea begins evacuating thousands of Scouts from coastal campsite as tropical storm nears

The high cost of giving birth even with insurance

Teen said 'homophobic slurs' before O'Shae Sibley killing: Criminal complaint

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

At least 12 people were injured in a blast at a port in northwest Turkey

Hollywood unions extend contract negotiations for actors

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Guidelines to prevent youth baseball injuries need more muscle

Pushing for an NIH office for post

Wikipedia

Bursting ice dam in Alaska highlights risks of glacial flooding around the globe

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

How many hemophilia patients actually want gene therapy?

DeSantis and Newsom agree to Sean Hannity debate, then disagree on the rules

Ebola: Gilead Sciences antiviral shows promise as new treatment

Moderna hits safety problems in bold bid to reinvent medicine

entertainment

focus

hotspot

leisure time